# US 2022/0024981 A1 · Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0024981 A1
- Document ID: US20220024981A1
- Status: Published application
- Kind: A1
- Application number: 17/296,679
- Filed: 2019-11-26
- Published: 2022-01-27
- Earliest claimed: 2018-11-27
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Alec Nathanson FLYER; Andrei Alexandrovich GOLOSOV; Philipp GROSCHE; Ian LEWIS; Eugene Yuejin LIU; Andreas MARZINZIK; Lauren Gilchrist MONOVICH; Johannes OTTL; Tajesh Jayprakash PATEL; Patrick Crawford REID; Mohindra SEEPERSAUD
- Web page: https://patentgrep.com/patent/US20220024981A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/06: Antihyperlipidemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure relates to inhibitors of PCSK9 useful in the treatment of lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are described herein.

## Claims

### Claim 1

A cyclic polypeptide of Formula (I) (SEQ ID No.: 39):
wherein:
R1 is H or (C1-C4)alkyl;
X1 is absent, Gly, Gly-L-Lys*, or Gly-D-Lys*, wherein * denotes the point of attachment to NHR1;
X2 is L-Pro or D-Pro;
X3 is L-Arg, D-Arg, L-Ser, D-Ser, L-His, D-His, L-Ala, or D-Ala;
X4 is L-Asp, D-Asp, L-Asn, D-Asn, L-Glu, D-Glu, L-Lys, D-Lys, L-Gln, D-Gln, L-Pro, D-Pro, L-Ala, D-Ala, L-(N-Me)Glu, or D-(N-Me)Glu;
X5 is L-(N-Me)Ala, D-(N-Me)Ala, L-(N-Me)Glu, or D-(N-Me)Glu;
X6 is L-Bip, D-Bip, L-(4-CF3)Phe, D-(4-CF3)Phe, L-(3,4-diCl)Phe, D-(3,4-diCl)Phe, L-(3-F)Phe, D-(3-F)Phe, L-(4-Cl)Phe, or D-(4-Cl)Phe;
X7 is L-(N-Me)Ala, D-(N-Me)Ala, L-(N-Me)Phe, or D-(N-Me)Phe;
X8 is L-Bip, D-Bip, L-Ser, D-Ser, L-Tyr, D-Tyr, L-(4-CF3)Phe, D-(4-CF3)Phe, L-Ala, D-Ala, L-Phe, D-Phe, L-Val, or D-Val;
X9 is L-Thr or D-Thr;
X10 is L-Thr, D-Thr, L-Ser, or D-Ser;
X11 is L-Ser, D-Ser, L-Asp, D-Asp, L-Asn, D-Asn, L-Pro, D-Pro, L-Ala, D-Ala, L-Hse, or D-Hse;
X12 is L-Val, D-Val, L-Glu or D-Glu; and
X13 is L-Phe or D-Phe;
wherein:
Bip is 4-phenyl-phenylalanine;
Hse is homoserine;
(4-CF3)Phe is 4-trifluoromethyl-phenylalanine;
(3,4-diCl)Phe is 3,4-dichloro-phenylalanine;
(3-F)Phe is 3-fluoro-phenylalanine; and
(4-Cl)Phe is 4-chloro-phenylalanine;
or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof.

### Claim 2 (depends on 1)

The cyclic polypeptide of claim 1, wherein (SEQ ID No.: 40):
R1 is H or (C1-C4)alkyl;
X1 is absent or Gly;
X2 is L-Pro or D-Pro;
X3 is L-Arg, D-Arg, L-Ser, D-Ser, L-His, D-His, L-Ala, or D-Ala;
X4 is L-Asp, D-Asp, L-Asn, D-Asn, L-Glu, D-Glu, L-Lys, D-Lys, L-Gln, D-Gln, L-Pro, D-Pro, L-Ala, D-Ala, L-(N-Me)Glu, or D-(N-Me)Glu;
X5 is L-(N-Me)Ala, D-(N-Me)Ala, L-(N-Me)Glu, or D-(N-Me)Glu;
X6 is L-Bip, D-Bip, L-(4-CF3)Phe, D-(4-CF3)Phe, L-(3,4-diCl)Phe, D-(3,4-diCl)Phe,
L-(3-F)Phe, D-(3-F)Phe, L-(4-Cl)Phe, or D-(4-Cl)Phe;
X7 is L-(N-Me)Ala, D-(N-Me)Ala, L-(N-Me)Phe, or D-(N-Me)Phe;
X8 is L-Bip, D-Bip, L-Ser, D-Ser, L-Tyr, D-Tyr, L-(4-CF3)Phe, D-(4-CF3)Phe, L-Ala, D-Ala, L-Phe, D-Phe, L-Val, or D-Val;
X9 is L-Thr or D-Thr;
X10 is L-Thr, D-Thr, L-Ser, or D-Ser;
X11 is L-Ser, D-Ser, L-Asp, D-Asp, L-Asn, D-Asn, L-Pro, D-Pro, L-Ala, D-Ala, L-Hse, or D-Hse;
X12 is L-Val, D-Val, L-Glu or D-Glu; and
X13 is L-Phe or D-Phe;
wherein:
Bip is 4-phenyl-phenylalanine;
Hse is homoserine;
(4-CF3)Phe is 4-trifluoromethyl-phenylalanine;
(3,4-diCl)Phe is 3,4-dichloro-phenylalanine;
(3-F)Phe is 3-fluoro-phenylalanine; and
(4-Cl)Phe is 4-chloro-phenylalanine;
or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof.

### Claim 3 (depends on 1, 2)

The cyclic polypeptide of claim 1 or 2, wherein X13 is L-Phe (SEQ ID No.: 41).

### Claim 4 (depends on 1, 2, 3)

The cyclic polypeptide of any one of claims 1-3, wherein X2 is L-Pro (SEQ ID No.: 42).

### Claim 5 (depends on 1, 2, 3, 4)

The cyclic polypeptide of any one of claims 1-4, wherein X9 is L-Thr (SEQ ID No.: 43).

### Claim 6 (depends on 1, 2)

The cyclic polypeptide of claim 1 or 2 having the following Formula (II) (SEQ ID No.: 44), (III) (SEQ ID No.: 45), (IV) (SEQ ID No.: 46), (V) (SEQ ID No.: 47), or (VI) (SEQ ID No.: 48):
or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The cyclic polypeptide of any one of claims 1-6, wherein X12 is L-Val or L-Glu (SEQ ID No.: 49).

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The cyclic polypeptide of any one of claims 1-7, wherein X12 is L-Val (SEQ ID No.: 50).

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The cyclic polypeptide of any one of claims 1-8, wherein X1 is absent (SEQ ID No.: 51).

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The cyclic polypeptide of any one of claims 1-8, wherein X1 is Gly (SEQ ID No.: 52).

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The cyclic polypeptide of any one of claims 1-10, wherein X10 is L-Thr or L-Ser (SEQ ID No.: 53).

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The cyclic polypeptide of any one of claims 1-11, wherein R1 is H or (C1-C3)alkyl (SEQ ID No.: 54).

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The cyclic polypeptide of any one of claims 1-12, wherein R1 is H (SEQ ID No.: 55).

### Claim 14 (depends on 1)

The cyclic polypeptide according to claim 1 selected from:
or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A pharmaceutical composition comprising a therapeutically effective amount of a cyclic polypeptide according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A combination comprising a polypeptide according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof, and one or more additional therapeutically active agents.

### Claim 17 (depends on 16)

The combination according to claim 16, wherein the additional therapeutically active agent is a statin.

### Claim 18 (depends on 15, 16, 17)

The pharmaceutical composition or combination according to any one of claims 15-17 for use in the treatment, prevention, amelioration, or delay in the progression of a PCSK9-mediated disease or disorder.

### Claim 19 (depends on 18)

The pharmaceutical composition or the combination according to claim 18, wherein said PCSK9-mediated disease or disorder or the disease or disorder requiring inhibition of PCSK9 activity is selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL, elevated triglycerides, sepsis, and xanthoma.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of modulating PCSK9 comprising administering to a patient in need thereof a cyclic polypeptide of any one of claims 1-14, or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of inhibiting PCSK9 comprising administering to a patient in need thereof a cyclic polypeptide of any one of claims 1-14, or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method for treating, preventing, ameliorating or delaying the progression of a PCSK9-mediated disease or disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount of a cyclic polypeptide according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 22)

The method of claim 22, wherein said PCSK9-mediated disease or disorder is selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL, elevated triglycerides, sepsis, and xanthoma.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of (i) reducing Lp(a), (ii) reducing Lp(a) plasma levels, (iii) reducing Lp(a) serum levels, (iv) reducing serum TRL or LDL levels, (v) reducing serum triglyceride levels, (vi) reducing LDL-C, (vii) reducing total plasma apoB concentrations, (viii) reducing LDL apoB, (ix) reducing TRL apoB, or (x) reducing non HDL-C, the method comprising administering to a patient in need thereof a therapeutically effective amount of a cyclic polypeptide of any one of claims 1-14, or a pharmaceutically acceptable salt thereof to the patient, thereby reducing LDL-C in the patient.

### Claim 25 (depends on 20, 21, 22, 23, 24)

The method of claims any one of claims 20-24, wherein administering is performed orally, parentally, subcutaneously, by injection, or by infusion.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A cyclic polypeptide according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof, for use in the treatment of a PCSK9-mediated disease or disorder.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A cyclic polypeptide according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof, for use in the treatment, prevention, amelioration or delay of progression or for use in the treatment, prevention, amelioration or delay of progression of a disease or disorder requiring inhibition of PCSK9.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

Use of a polypeptide according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof, for the treatment, prevention, amelioration or delay of progression of a PCSK9-mediated disease or disorder or for the treatment, prevention, amelioration or delay of progression of a disease or disorder requiring inhibition of PCSK9.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

Use of a polypeptide according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment, prevention, amelioration or delay of progression of a PCSK9-mediated disease or disorder or for the treatment, prevention, amelioration or delay of progression of a disease or disorder requiring inhibition of PCSK9.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method for treating, preventing, ameliorating or delaying the progression of a PCSK9-mediated disease or disorder or of disease or disorder requiring inhibition of PCSK9 or of PCSK9 activity comprising the step of administering to a patient in need thereof a therapeutically effective amount of a polypeptide according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 27, 28, 29, 30)

The polypeptide for use according to claim 27, the use of a polypeptide according to claim 28 or 29, or the method for according to claim 30, wherein said PCSK9-mediated disease or disorder or the disease or disorder requiring inhibition of PCSK9 is selected from hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral vascular disease, peripheral arterial disease, vascular inflammation, elevated Lp(a), elevated LDL, elevated TRL, elevated triglycerides, sepsis, and xanthoma.
